- decreased bone mineral density / IMPC
- increased circulating calcium level / IMPC
- abnormal retina morphology / IMPC
- increased circulating triglyceride level / IMPC
- increased circulating phosphate level / IMPC
- decreased circulating alkaline phosphatase level / IMPC
- increased total body fat amount / IMPC
- decreased bone mineral content / IMPC
C57BL/6N-Txniptm1b(EUCOMM)Hmgu/H
| Status | Only small colony available |
| EMMA ID | EM:16332 |
| Citation information | RRID:IMSR_EM:16332 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | C57BL/6N-Txniptm1b(EUCOMM)Hmgu/H |
| Alternative name | HEPD0732_5_F08 |
| Strain type | Targeted Mutant Strains |
| Allele/Transgene symbol | Txniptm1b(EUCOMM)Hmgu |
| Gene/Transgene symbol | Txnip |
| Disclaimer | Please note that for EUCOMM and KOMP-CSD mice supplied to the scientific community by INFRAFRONTIER/EMMA:
|
Information from provider
| Provider | Mary Lyon Centre at MRC Harwell |
| Provider affiliation | Mary Lyon Centre at MRC Harwell |
| Genetic information | This mouse line originates from EUCOMM ES clone HEPD0732_5_F08. For further details on the construction of this clone see the page at the IMPC portal. The critical exon(s) were flanked by loxP sites, and subsequent cre expression excised this critical sequence resulting in a knockout reporter allele. Click here for more information on EUCOMM final vectors. |
| Phenotypic information | Potential phenotyping data in the IMPC portal |
| References | None available |
Information from EMMA
| Archiving centre | Mary Lyon Centre at MRC Harwell, Oxford, United Kingdom |
Disease and phenotype information
IMPC phenotypes (allele matching)
IMPC phenotypes (gene matching)
- increased circulating triglyceride level / IMPC
- decreased bone mineral content / IMPC
- increased circulating calcium level / IMPC
- abnormal retina morphology / IMPC
- increased total body fat amount / IMPC
- decreased bone mineral density / IMPC
- decreased circulating alkaline phosphatase level / IMPC
- increased circulating phosphate level / IMPC
MGI phenotypes (gene matching)
- hypoglycemia / MGI
- increased circulating triglyceride level / MGI
- increased circulating free fatty acid level / MGI
- abnormal circulating insulin level / MGI
- abnormal glucose homeostasis / MGI
- abnormal lipid homeostasis / MGI
- no abnormal phenotype detected / MGI
- increased circulating ketone body level / MGI
- abnormal ileum morphology / MGI
- hepatic steatosis / MGI
- increased insulin sensitivity / MGI
- increased liver weight / MGI
- liver degeneration / MGI
- increased hepatocellular carcinoma incidence / MGI
- abnormal gluconeogenesis / MGI
- kidney failure / MGI
- abnormal heart left ventricle morphology / MGI
- impaired cellular glucose import / MGI
- altered response of heart to induced stress / MGI
- increased regulatory T cell number / MGI
- increased lymphocyte cell number / MGI
- abnormal NK cell morphology / MGI
- increased circulating VLDL cholesterol level / MGI
- hematuria / MGI
- increased circulating cholesterol level / MGI
- abnormal mesenteric lymph node morphology / MGI
- increased fatty acid level / MGI
- improved glucose tolerance / MGI
- increased T cell proliferation / MGI
- homeostasis/metabolism phenotype / MGI
- growth/size/body region phenotype / MGI
- cardiovascular system phenotype / MGI
- reproductive system phenotype / MGI
- decreased circulating glucose level / MGI
- increased blood urea nitrogen level / MGI
- decreased ventricle muscle contractility / MGI
- increased bleeding time / MGI
- increased circulating potassium level / MGI
- decreased circulating sodium level / MGI
- abnormal circulating phospholipid level / MGI
- decreased NK T cell number / MGI
- decreased NK cell number / MGI
- decreased CD8-positive, alpha-beta T cell number / MGI
- decreased physiological sensitivity to xenobiotic / MGI
- abnormal blood homeostasis / MGI
- increased sensitivity to induced morbidity/mortality / MGI
- abnormal NK cell physiology / MGI
- mortality/aging / MGI
- abnormal cellular respiration / MGI
- decreased circulating antithrombin level / MGI
- increased prothrombin time / MGI
- increased partial thromboplastin time / MGI
- increased circulating lactate level / MGI
- increased cardiac cell glucose uptake / MGI
- increased muscle cell glucose uptake / MGI
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).
